



ACURATE *neo2*[™] Aortic Valve System

ACURATE *neo2* CE-Mark Study

Transcatheter Aortic Valve Implantation for Severe Aortic Valve Stenosis with the ACURATE *neo2* Valve System:
30-day Safety and Performance Outcomes

Möhlmann H; Presented PCRLV 2018, London, September 10, 2018

Transcatheter Aortic Valve Replacement with the ACURATE *neo2* Valve System: 1-Year Clinical and Hemodynamic Outcomes

Möhlmann H; Presented TVT 2019, Chicago, June 13, 2019

Study Design

Prospective, single-arm, multicenter study of 120 patients at 9 European sites evaluating the safety and performance of the ACURATE *neo2* Aortic Valve System (device in study named “ACURATE *neo* AS”).

Primary endpoint was all-cause mortality at 30 days; key secondary endpoints include VARC-2 clinical events at discharge, 30 days, and 1 year as well as hemodynamic function and aortic regurgitation. Independent assessment of clinical data including core-laboratory analysis of echocardiographic data.

Procedural Characteristics

Procedural efficiency demonstrated with high rate of correct valve positioning (98.3%), procedural success (97.5%), and short device usage time (3.9 min) with no incidence of coronary occlusion.

Procedural Characteristics	
Correct positioning of a single valve in the proper location	98.3%
Procedural success*	97.5%
Peri-procedural MI (≤ 72h)	0.0%
Device usage time**	3.9 ± 3.5 min

* In 2 patients, valve-in-valve implantation of a non-study valve was required (valve embolization, n=1; valve dislodgement/migration, n=1);


In 1 patient, post-dilatation resulted in ventricular septal perforation and conversion to open-heart surgery

** Time from femoral insertion to withdrawal of delivery system

Clinical Highlights

Low complication rates, in line with other third-generation TAVI systems.



Single-digit transvalvular gradients and large EOAs demonstrated at discharge and further improved at 30 days and 1 year. Most pacemaker recipients (56%) had conduction system disturbances already at baseline.



Low PVL rates and excellent hemodynamic performance.

Core lab adjudicated PVL rates are lower with ACURATE neo2 than previously reported with ACURATE neo

- 97% of patients ≤ mild PVL, 3% of patients had moderate, and no PVL more than moderate was observed at 30 days
- Results confirmed at 1 year with 97.5% of patients ≤ mild PVL (60.5% none/trace, 37% mild) and only 2.5% of patients with moderate PVL; no patients with severe PVL



All trademarks are the property of their respective owners.

CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labeling supplied with each device. Information for use only in countries with applicable health authority product registrations. Information not for use or distribution in France.

SH-655503-AA

Boston Scientific
Advancing science for life™

© 2020 Boston Scientific Corporation or its affiliates. All rights reserved.

DINSH0245EA